Ipsen

Pharmaceuticals
IPN.PA
€ 108 0
Share price
$ 9.4 bn
Market Cap
$ 9.5 bn
Enterprise Value

Carbon footprint

2 Ton
GHG emissions per $ 1 mln investment
0.05x the weighted average for S&P 500
FY2021
How is this calculated?
-5.2%
YOY change in GHG emissions
Weaker than the +4.2% weighted average for S&P 500
FY2021 vs. previous year

Primary Climate Goal

-4%
Proj. YOY change in GHG emissions (Scope 1 + 2)
Weaker than the -6.6% weighted average for S&P 500
FY2022
How is this calculated?

Ipsen aims to reduce Scope 1 + 2 by 50% by 2030 from a base year 2019


1.5°C
Ipsen's actual and proj. GHG emissions (Scope 1 + 2) (Kt of CO2e)

GHG emissions and Carbon intensity

Ipsen's GHG emissions (market-based) (Kt of CO2e)
Ipsen's Carbon intensity (Tons per 1 USDm)

Ipsen's carbon footprint

Ipsen reported Total CO2e Emissions - Market-Based Scope 1 + Scope 2 for the twelve months ending 31 December 2021 at 19 Kt (-1.1 /-5.2% y-o-y). Also positively, carbon intensity decreased sharply to 5.4 t (-1.1 /-16.9% y-o-y).

Ipsen's Scope 3 emissions declined marginally to 32 Kt (-0.09 /-0.3% y-o-y). The rate of decline has slowed vs. the previous periods (CAGR -23.4% since 4Q'18).

The company is committed to reducing Scope 1 + 2 by 50% by 2030 from a base year 2019, which translates into the estimated reduction of -0.76 Kt per annum over the period of FY2022 - FY2030. This science-based target is aligned with Paris Agreement to limit global warming to 1.5°C above pre-industrial levels.

Company environmental metrics

Show more...